Literature DB >> 17702711

Idiopathic IgA nephropathy: pathogenesis, histopathology, and therapeutic options.

James A Tumlin1, Michael P Madaio, Randolph Hennigar.   

Abstract

IgA nephropathy is one of the most common causes of glomerulonephritis in the world. Proliferative and crescentic forms of IgA are found in up to 30% of cases and are associated with nephrotic-range proteinuria, accelerated hypertension, and accelerated decline toward ESRD. Despite its prevalence and clinical importance, there is no unifying nomenclature or consensus for the treatment of specific histologic subgroups. As a consequence, the development of clinically effective treatment regimens for IgA nephropathy have lagged behind other, less common forms of glomerulonephritis. Herein is reviewed the pathogenesis and histologic subtypes of IgA nephropathy and how conventional and immunosuppressive therapies have an impact on renal survival and recurrence rates. The use of known clinical risk factors for disease progression in conjunction with specific histologic features can be a guide to both induction and consolidation therapies for individual patients with IgA nephropathy.

Entities:  

Mesh:

Year:  2007        PMID: 17702711     DOI: 10.2215/CJN.04351206

Source DB:  PubMed          Journal:  Clin J Am Soc Nephrol        ISSN: 1555-9041            Impact factor:   8.237


  19 in total

Review 1.  IgA nephropathy: clearance kinetics of IgA-containing immune complexes.

Authors:  Ann Chen; Sung-Sen Yang; Tsai-Jung Lin; Shuk-Man Ka
Journal:  Semin Immunopathol       Date:  2018-09-14       Impact factor: 9.623

Review 2.  Cellular senescence in renal ageing and disease.

Authors:  Ines Sturmlechner; Matej Durik; Cynthia J Sieben; Darren J Baker; Jan M van Deursen
Journal:  Nat Rev Nephrol       Date:  2016-12-28       Impact factor: 28.314

3.  Pauci-immune Crescentic Glomerulonephritis in a Patient With Immunoglobulin A Nephropathy and Serum Antineutrophil Cytoplasmic Autoantibody Positivity.

Authors:  Keren Cohen-Hagai; Sydney Benchetrit; Osnat Klein; Yona Kitay-Cohen; Ze'ev Korzets
Journal:  Arch Rheumatol       Date:  2017-09-13       Impact factor: 1.472

4.  Chronic kidney disease prevention--a challenge for Asian countries: report of the Third Asian Forum of Chronic Kidney Disease Initiatives.

Authors:  Jer-Ming Chang; Shang-Jyh Hwang; Yusuke Tsukamoto; Hung-Chun Chen
Journal:  Clin Exp Nephrol       Date:  2012-03-03       Impact factor: 2.801

5.  Independent or synergistic relationship of proteinuria and glomerular filtration rate on patient and renal survival in patients with glomerulonephritis?

Authors:  Dominik G Haider; Salome Masghati; Georg Goliasch; Valentin Fuhrmann; Afschin Soleiman; Michael Wolzt; Andreas Baierl; Wilfred Druml; Walter H Hörl
Journal:  J Nephrol       Date:  2014-03-08       Impact factor: 3.902

6.  Comparison of inhibitors of renin-angiotensin-aldosterone system (RAS) and combination therapy of steroids plus RAS inhibitors for patients with advanced immunoglobulin A nephropathy and impaired renal function.

Authors:  Takahito Moriyama; Kayu Nakayama; Ayami Ochi; Nobuyuki Amemiya; Yuki Tsuruta; Chiari Kojima; Mitsuyo Itabashi; Takashi Takei; Keiko Uchida; Kosaku Nitta
Journal:  Clin Exp Nephrol       Date:  2011-10-26       Impact factor: 2.801

Review 7.  Mesangial pathology in glomerular disease: targets for therapeutic intervention.

Authors:  Yogesh M Scindia; Umesh S Deshmukh; Harini Bagavant
Journal:  Adv Drug Deliv Rev       Date:  2010-09-07       Impact factor: 15.470

8.  IgA nephropathy with minimal change disease.

Authors:  Leal C Herlitz; Andrew S Bomback; Michael B Stokes; Jai Radhakrishnan; Vivette D D'Agati; Glen S Markowitz
Journal:  Clin J Am Soc Nephrol       Date:  2014-04-10       Impact factor: 8.237

9.  Chronic kidney disease in an adult with propionic acidemia.

Authors:  H J Vernon; S Bagnasco; A Hamosh; C J Sperati
Journal:  JIMD Rep       Date:  2013-06-12

10.  A case of crescentic IgA nephropathy treated with prednisolone and cyclophosphamide.

Authors:  E Sengul; T Eyileten; A Ozcan; M I Yilmaz; M Yenicesu
Journal:  Hippokratia       Date:  2009-07       Impact factor: 0.471

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.